Literature DB >> 24596398

Interferon regulatory factor 3 protects against adverse neo-intima formation.

Shu-Min Zhang1, Li-Hua Zhu1, Zuo-Zhi Li2, Pi-Xiao Wang1, Hou-Zao Chen2, Hong-Jing Guan1, Ding-Sheng Jiang1, Ke Chen3, Xiao-Fei Zhang3, Song Tian1, Da Yang1, Xiao-Dong Zhang2, Hongliang Li4.   

Abstract

AIMS: Vascular smooth muscle cell (VSMC) proliferation is central to the pathophysiology of neo-intima formation. Interferon regulatory factor 3 (IRF3) inhibits the growth of cancer cells and fibroblasts. However, the role of IRF3 in vascular neo-intima formation is unknown. We evaluated the protective role of IRF3 against neo-intima formation in mice and the underlying mechanisms. METHODS AND
RESULTS: IRF3 expression was down-regulated in VSMCs after carotid wire injury in vivo, and in SMCs after platelet-derived growth factor (PDGF)-BB challenge in vitro. Global knockout of IRF3 (IRF3-KO) led to accelerated neo-intima formation and proliferation of VSMCs, whereas the opposite was seen in SMC-specific IRF3 transgenic mice. Mechanistically, we identified IRF3 as a novel regulator of peroxisome proliferator-activated receptor γ (PPARγ), a negative regulator of SMC proliferation after vascular injury. Binding of IRF3 to the AB domain of PPARγ in the nucleus of SMCs facilitated PPARγ transactivation, resulting in decreased proliferation cell nuclear antigen expression and suppressed proliferation. Overexpression of wild-type, but not truncated, IRF3 with a mutated IRF association domain (IAD) retained the ability to exert anti-proliferative effect.
CONCLUSIONS: IRF3 inhibits VSMC proliferation and neo-intima formation after vascular injury through PPARγ activation. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  IRF3; Neo-intima formation; PPARγ; Proliferation

Mesh:

Substances:

Year:  2014        PMID: 24596398     DOI: 10.1093/cvr/cvu052

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  4 in total

Review 1.  The interferon regulatory factors as novel potential targets in the treatment of cardiovascular diseases.

Authors:  Xiao-Jing Zhang; Ding-Sheng Jiang; Hongliang Li
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

2.  Upregulation of IRF9 Contributes to Pulmonary Artery Smooth Muscle Cell Proliferation During Pulmonary Arterial Hypertension.

Authors:  Yong-Jie Chen; Yi Li; Xian Guo; Bo Huo; Yue Chen; Yi He; Rui Xiao; Xue-Hai Zhu; Ding-Sheng Jiang; Xiang Wei
Journal:  Front Pharmacol       Date:  2021-12-01       Impact factor: 5.810

3.  JIB-04, a histone demethylase Jumonji C domain inhibitor, regulates phenotypic switching of vascular smooth muscle cells.

Authors:  Yi He; Xin Yi; Zihao Zhang; Hanshen Luo; Rui Li; Xin Feng; Ze-Min Fang; Xue-Hai Zhu; Wenlin Cheng; Ding-Sheng Jiang; Fang Zhao; Xiang Wei
Journal:  Clin Epigenetics       Date:  2022-08-13       Impact factor: 7.259

4.  Interferon regulatory factor 7 protects against vascular smooth muscle cell proliferation and neointima formation.

Authors:  Ling Huang; Shu-Min Zhang; Peng Zhang; Xiao-Jing Zhang; Li-Hua Zhu; Ke Chen; Lu Gao; Yan Zhang; Xiang-Jie Kong; Song Tian; Xiao-Dong Zhang; Hongliang Li
Journal:  J Am Heart Assoc       Date:  2014-10-10       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.